FI961285A0 - CD40:n vasta-aineita - Google Patents

CD40:n vasta-aineita

Info

Publication number
FI961285A0
FI961285A0 FI961285A FI961285A FI961285A0 FI 961285 A0 FI961285 A0 FI 961285A0 FI 961285 A FI961285 A FI 961285A FI 961285 A FI961285 A FI 961285A FI 961285 A0 FI961285 A0 FI 961285A0
Authority
FI
Finland
Prior art keywords
antibodies
binding
ligand
monoclonal antibodies
specifically bind
Prior art date
Application number
FI961285A
Other languages
English (en)
Swedish (sv)
Other versions
FI961285A (fi
Inventor
William C Fanslow
Jodee Zappone
Mark Alderson
Richard J Armitage
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of FI961285A0 publication Critical patent/FI961285A0/fi
Publication of FI961285A publication Critical patent/FI961285A/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI961285A 1993-10-01 1996-03-20 CD40:n vasta-aineita FI961285A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13054193A 1993-10-01 1993-10-01
PCT/US1994/009984 WO1995009653A1 (en) 1993-10-01 1994-09-02 Antibodies to cd40

Publications (2)

Publication Number Publication Date
FI961285A0 true FI961285A0 (fi) 1996-03-20
FI961285A FI961285A (fi) 1996-03-20

Family

ID=22445171

Family Applications (1)

Application Number Title Priority Date Filing Date
FI961285A FI961285A (fi) 1993-10-01 1996-03-20 CD40:n vasta-aineita

Country Status (15)

Country Link
US (1) US5801227A (fi)
EP (1) EP0724456B1 (fi)
JP (1) JP3675819B2 (fi)
KR (1) KR960704576A (fi)
AT (1) ATE255906T1 (fi)
AU (1) AU686230B2 (fi)
CA (1) CA2172376C (fi)
DE (1) DE69433406T2 (fi)
DK (1) DK0724456T3 (fi)
ES (1) ES2211884T3 (fi)
FI (1) FI961285A (fi)
NO (1) NO961151L (fi)
NZ (1) NZ273504A (fi)
PT (1) PT724456E (fi)
WO (1) WO1995009653A1 (fi)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874082A (en) * 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
ATE220331T1 (de) * 1995-03-01 2002-07-15 Immunex Corp Cd40 bindendes protein zur stimulierung der immunantwort
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
US20020102706A1 (en) * 1997-06-18 2002-08-01 Genentech, Inc. Apo-2DcR
JP2002508663A (ja) * 1997-06-18 2002-03-19 ジェネンテク，インコーポレイテッド Ａｐｏ−２ＤｃＲ
DK1616579T3 (da) * 1998-05-23 2009-09-14 Univ Leiden Medical Ct CD40 bindende molekyler og CTL peptider til behandling af tumorer
AU4685900A (en) 1999-04-30 2000-11-17 La Jolla Institute For Allergy And Immunology Methods for preventing reactivation of latent virus and controlling virus replication
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
DE60035057T2 (de) * 1999-10-04 2008-01-31 Novartis Vaccines and Diagnostics, Inc., Emeryville CD40 Antagonist zur Behandlung von Psoriasis
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
JP2003524644A (ja) 2000-02-01 2003-08-19 タノックス インコーポレイテッド Ｃｄ４０−結合性ａｐｃ−活性化分子
CA2405632A1 (en) * 2000-04-25 2001-11-01 Idec Pharmaceutical Corporation Intrathecal administration of rituximab for treatment of central nervous system lymphomas
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
WO2001083755A2 (en) * 2000-04-28 2001-11-08 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
PT1326896E (pt) 2000-10-02 2011-03-03 Novartis Vaccines & Diagnostic Anticorpos humanos anti-cd40
US20030211107A1 (en) * 2002-01-31 2003-11-13 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
EP1372724A2 (en) 2001-01-31 2004-01-02 Idec Pharmaceuticals Corporation Use of immunoregulatory antibodies in the treatment of neoplastic disorders
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
US20070065436A1 (en) * 2001-01-31 2007-03-22 Biogen Idec Inc. Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
US20020159996A1 (en) * 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
CN101508734A (zh) * 2001-04-27 2009-08-19 协和发酵麒麟株式会社 抗cd40单克隆抗体
AU2002347404A1 (en) * 2001-09-14 2003-04-01 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
US20030180292A1 (en) * 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
CA2544852A1 (en) * 2003-11-04 2005-05-19 Chiron Corporation Methods of therapy for solid tumors expressing the cd40 cell-surface antigen
US20050136055A1 (en) 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
CN1980957A (zh) 2004-03-23 2007-06-13 比奥根艾迪克Ma公司 受体偶联剂及其治疗用途
US20080057070A1 (en) * 2004-11-04 2008-03-06 Chiron Corporation Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
JP2009513712A (ja) * 2005-11-01 2009-04-02 ノバルティス アーゲー 抗ｃｄ４０抗体の使用
RU2442605C2 (ru) * 2005-11-01 2012-02-20 Новартис Аг Применения антител против cd40
AU2007240507B2 (en) 2006-04-21 2013-07-18 Novartis Ag Antagonist anti-CD40 antibody pharmaceutical compositions
AU2007248628B2 (en) 2006-05-03 2013-02-07 The Regents Of The University Of Colorado, A Body Corporate CD40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
PT3556774T (pt) 2011-03-11 2024-02-29 Beth Israel Deaconess Medical Ct Inc Anticorpos anti-cd40 e suas utilizações
CN103635488B (zh) 2011-04-29 2016-12-14 埃派斯进有限公司 抗-cd40抗体及其使用方法
CA2888763A1 (en) 2012-10-30 2014-05-08 Apexigen, Inc. Anti-cd40 antibodies and methods of use
SI3303395T1 (sl) 2015-05-29 2020-03-31 Abbvie Inc. Protitelesa proti CD40 in njihove uporabe
MX2018002708A (es) 2015-09-04 2018-08-01 Primatope Therapeutics Inc Anticuerpos anti-cd40 humanizados y usos de los mismos.
AU2016329057A1 (en) 2015-09-30 2018-04-12 Janssen Biotech, Inc. Antagonistic antibodies specifically binding human CD40 and methods of use
US11497781B2 (en) 2016-03-10 2022-11-15 Cg Oncology, Inc. Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor
WO2017184619A2 (en) 2016-04-18 2017-10-26 Celldex Therapeutics, Inc. Agonistic antibodies that bind human cd40 and uses thereof
CN109475603B (zh) 2016-06-20 2023-06-13 科马布有限公司 抗pd-l1抗体
KR102019033B1 (ko) * 2016-11-11 2019-09-06 다이노나(주) Cd40에 특이적으로 결합하는 항체 및 그의 용도
CN117500816A (zh) 2021-08-26 2024-02-02 映恩生物制药（苏州）有限公司 一种甾体化合物及其缀合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5247069A (en) * 1986-06-13 1993-09-21 Oncogen Ligands and methods for augmenting B-cell proliferation
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules

Also Published As

Publication number Publication date
AU686230B2 (en) 1998-02-05
NZ273504A (en) 1997-12-19
DE69433406D1 (de) 2004-01-22
ES2211884T3 (es) 2004-07-16
US5801227A (en) 1998-09-01
WO1995009653A1 (en) 1995-04-13
DE69433406T2 (de) 2004-10-07
JP3675819B2 (ja) 2005-07-27
CA2172376A1 (en) 1995-04-13
PT724456E (pt) 2004-04-30
AU7681994A (en) 1995-05-01
EP0724456A1 (en) 1996-08-07
ATE255906T1 (de) 2003-12-15
DK0724456T3 (da) 2004-04-13
EP0724456A4 (en) 1997-07-02
KR960704576A (ko) 1996-10-09
NO961151D0 (no) 1996-03-21
FI961285A (fi) 1996-03-20
CA2172376C (en) 2008-11-18
JPH09504169A (ja) 1997-04-28
EP0724456B1 (en) 2003-12-10
NO961151L (no) 1996-03-21

Similar Documents

Publication Publication Date Title
FI961285A (fi) CD40:n vasta-aineita
DE69429925T2 (de) METHODE ZUR BINDUNG VON MATERIAL AN DAS Beta-AMYLOID-PEPTID
ES2106195T3 (es) Anticuerpo igg aglicosilado anti cd3.
FI962958A (fi) Humanisoituja vasta-aineita leukosyyttitarttumismolekyyliä VLA-4 vastaan
DE69233735D1 (de) Bindungsdomänen des Delta-proteins
CA2064915A1 (en) Tumour necrosis factor binding ligands
AU2821195A (en) Cross-reacting monoclonal antibodies specific for e-selectin and p-selectin
ZA946767B (en) Monocional antibodies having property of causing apoptosis.
DE68914244T2 (de) Monoklonaler Antikörper.
DK0812206T3 (da) Fremgangsmåde til stimulering af en immunrespons
DE3586216D1 (de) Brusttumorassoziiertes antigen und monoklonale antikoerper dazu.
NO890116L (no) Monoklonale antistoffer.
NO903788D0 (no) Monoklonalt antistoff mot protein c.
NO911300D0 (no) Homoklonale antistoffer mot reseptor-fremkalte bindingsseter.
DE68916088T2 (de) Anti-CPBII-monoklonaler Antikörper.
HUP0003029A2 (hu) Ankrod specifikus monoklonális antitestek, antitestfragmentumok, keverékeik és alkalmazásuk
GB2333295A (en) Modified protein G and fragments thereof